CD274 and neoplasm: This immune checkpoint molecule can be expressed by cancer cells and immune cells, as T and B lymphocytes, macrophages and dendritic cells, being its expression on tumor-infiltrating lymphocytes (TILs) correlated with clinical response to anti-PD-L1-targeted immunotherapy (atezolizumab) [16].